Medicare Drug Negotiation Survives Industry Challenge

The Fifth Circuit unanimously rejected the drug industry's challenge to Medicare price negotiation, leaving negotiated prices for 15 additional drugs on track for January 2027. The ruling strengthens the policy's legal position but keeps implementation, beneficiary savings, drugmaker responses, and possible further appeals in focus; a separate Glenmark generic-price-fixing settlement adds a consumer-affordability angle.